JP2023143850A - コロナウイルス感染症予防用組成物 - Google Patents
コロナウイルス感染症予防用組成物 Download PDFInfo
- Publication number
- JP2023143850A JP2023143850A JP2023045934A JP2023045934A JP2023143850A JP 2023143850 A JP2023143850 A JP 2023143850A JP 2023045934 A JP2023045934 A JP 2023045934A JP 2023045934 A JP2023045934 A JP 2023045934A JP 2023143850 A JP2023143850 A JP 2023143850A
- Authority
- JP
- Japan
- Prior art keywords
- cona
- composition
- coronavirus
- oral cavity
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 208000001528 Coronaviridae Infections Diseases 0.000 title claims abstract description 37
- 108010062580 Concanavalin A Proteins 0.000 claims abstract description 103
- 210000000214 mouth Anatomy 0.000 claims abstract description 46
- 210000003800 pharynx Anatomy 0.000 claims abstract description 24
- 210000000867 larynx Anatomy 0.000 claims abstract description 23
- 239000000843 powder Substances 0.000 claims description 28
- 235000009508 confectionery Nutrition 0.000 claims description 20
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 11
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 11
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 11
- 239000000920 calcium hydroxide Substances 0.000 claims description 11
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 241000711573 Coronaviridae Species 0.000 abstract description 33
- 241000700605 Viruses Species 0.000 abstract description 28
- 239000000243 solution Substances 0.000 abstract description 27
- 208000015181 infectious disease Diseases 0.000 abstract description 23
- 101710198474 Spike protein Proteins 0.000 abstract description 9
- 229940096437 Protein S Drugs 0.000 abstract description 8
- 210000002919 epithelial cell Anatomy 0.000 abstract description 5
- 238000002347 injection Methods 0.000 abstract description 5
- 239000007924 injection Substances 0.000 abstract description 5
- 230000000069 prophylactic effect Effects 0.000 abstract description 4
- 210000002345 respiratory system Anatomy 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 22
- 239000000306 component Substances 0.000 description 22
- 230000000694 effects Effects 0.000 description 22
- 230000000840 anti-viral effect Effects 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 235000013305 food Nutrition 0.000 description 14
- 108010087870 Mannose-Binding Lectin Proteins 0.000 description 13
- 102000009112 Mannose-Binding Lectin Human genes 0.000 description 13
- 239000004480 active ingredient Substances 0.000 description 12
- 239000000523 sample Substances 0.000 description 11
- 230000003449 preventive effect Effects 0.000 description 10
- 241000251511 Holothuroidea Species 0.000 description 9
- 241000315672 SARS coronavirus Species 0.000 description 9
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000009385 viral infection Effects 0.000 description 8
- 208000036142 Viral infection Diseases 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 210000003296 saliva Anatomy 0.000 description 7
- 229960005486 vaccine Drugs 0.000 description 7
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 6
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 239000007790 solid phase Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 102000018265 Virus Receptors Human genes 0.000 description 5
- 108010066342 Virus Receptors Proteins 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 238000011088 calibration curve Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 239000012085 test solution Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 210000004748 cultured cell Anatomy 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 241000282552 Chlorocebus aethiops Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 210000000621 bronchi Anatomy 0.000 description 3
- 230000004154 complement system Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 210000001331 nose Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229930003799 tocopherol Natural products 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000288673 Chiroptera Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 101001056128 Homo sapiens Mannose-binding protein C Proteins 0.000 description 2
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 2
- 241000482741 Human coronavirus NL63 Species 0.000 description 2
- FSBIGDSBMBYOPN-VKHMYHEASA-N L-canavanine Chemical compound OC(=O)[C@@H](N)CCONC(N)=N FSBIGDSBMBYOPN-VKHMYHEASA-N 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 2
- FSBIGDSBMBYOPN-UHFFFAOYSA-N O-guanidino-DL-homoserine Natural products OC(=O)C(N)CCON=C(N)N FSBIGDSBMBYOPN-UHFFFAOYSA-N 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 2
- 108010046334 Urease Proteins 0.000 description 2
- 238000011481 absorbance measurement Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 108700021021 mRNA Vaccine Proteins 0.000 description 2
- 229940126582 mRNA vaccine Drugs 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 238000012113 quantitative test Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000494545 Cordyline virus 2 Species 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000711467 Human coronavirus 229E Species 0.000 description 1
- 241001109669 Human coronavirus HKU1 Species 0.000 description 1
- 241001428935 Human coronavirus OC43 Species 0.000 description 1
- 235000019738 Limestone Nutrition 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 241001481166 Nautilus Species 0.000 description 1
- 241000283966 Pholidota <mammal> Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 208000035472 Zoonoses Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- LVXHNCUCBXIIPE-UHFFFAOYSA-L disodium;hydrogen phosphate;hydrate Chemical compound O.[Na+].[Na+].OP([O-])([O-])=O LVXHNCUCBXIIPE-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- -1 etc.) Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 235000010985 glycerol esters of wood rosin Nutrition 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000006028 limestone Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Confectionery (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
<コンカナバリンAの新型コロナウイルスに対する抗ウイルス試験1>
供試材料としてコンカナバリンA(ConA)(生化学用、富士フイルム和光純薬社製)を、供試ウイルスとして新型コロナウイルス(SARS-CoV-2)を、感受性細胞としてアフリカミドリザル腎臓継代細胞(VeroE6/TMPRSS2細胞)を用いた。
<コンカナバリンAの新型コロナウイルスに対する抗ウイルス試験2>
培養したVeroE6細胞にSARS-CoV-2を接種する際に、同時に添加するConA溶液のpHを0.01Nの水酸化ナトリウム水溶液を用いて下記表2の6段階に調整したこと以外は、実施例1と同様にしてConAの抗ウイルス効果を確認した。結果を下記表2及び図4に示す。
<ナタマメ粉末中のコンカナバリンA含有量の定量試験>
ELISA法によりナタマメ粉末中のConA含有量を定量した。標準サンプルの吸光度測定結果から検量線を作成し、試験サンプルの吸光度測定結果を当てはめることでConA含有量を算出した。
ナタマメ粉末1gに8mLの溶解用バッファを加え、室温で振盪攪拌して溶解した。この溶解液を低速遠心分離(200×g、3分、20℃)し、上清を回収して試験サンプルとした。
固相抗体として非結合ウサギ抗ConA抗体(EY Laboratories社製、Cat No.AL-1104-2)を用いた。これを固相液の0.005M炭酸バッファ(pH9.5)で0.5μg/mLに希釈した。この溶液を十分に攪拌した後、96ウェルプレート(Nunc社製、Cat No.468667)の各ウェルに100μLずつ分注した。4℃で一晩静置して固相した後、洗浄液(0.05M PBS,1.45M NaCl,0.5% Tween-20)で3回洗浄した。各ウェルにブロッキング液(1wt% Perfect-Block溶液、MOB社製、Cat No.PB01)を200μLずつ分注して固相プレートを作製した。
標識抗体としてヤギ抗ConAポリクローナル抗体(HRP標識)(OriGene Technologies社製、Cat No.AP21430HR-N)を用いた。バックグラウンドを低減するために、次のように標識抗体にウサギ血清を加えて吸収処理を行った。0.1%BSA/PBSにタンパク濃度が1mg/1mLになるよう正常ウサギ血清(タンパク濃度76.2mg/mL)を添加し、この溶液で標識抗体を100倍希釈した後、4℃で一晩静置した。
検量線の作成のため、生化学用のConA(富士フイルム和光純薬社製、製品コード031-08774)を、PBSで下記表3の濃度になるように希釈して標準サンプルとした。
作製した固相プレートの各ウェルを300μLの洗浄液で3回洗浄した。次に各ウェルに希釈した標準サンプル及び試験サンプルのConA溶液を100μLずつ添加して37℃で30分間静置した。その後各ウェルを300μLの洗浄液で3回洗浄した。次に調製した標識抗体をPBSでさらに250倍に希釈(最終的に25000倍に希釈)し、各ウェルに100μLずつ添加して37℃で30分間静置した。その後各ウェルを300μLの洗浄液で3回洗浄した。
<ナタマメ粉末配合飴溶解液の新型コロナウイルスに対する抗ウイルス試験1>
水飴にナタマメ粉末(ConA含有量4.65wt%)が2wt%になるように配合し80℃以下の温度で混練して3gの飴生地を調製した。この飴生地3gを5mLのPBSで溶解した。この飴溶解液中のConA濃度は560μg/mLとなる。
<ナタマメ粉末配合飴溶解液の新型コロナウイルスに対する抗ウイルス試験2>
実施例3で調製したナタマメ粉末を配合したConA濃度40μg/mLでpH10.0の飴溶解液を試験液Aとし、対照サンプルとして滅菌リン酸緩衝液を試験液Bとした。
減少率(%)=((対照区-試験区)/対照区)×100
Claims (6)
- コンカナバリンA(ConA)とアルカリ成分とを含有し、口腔内に投与されることを特徴とする、コロナウイルス感染症予防用組成物。
- 口腔内、咽頭部又は喉頭部の一部又は全部において、コンカナバリンA(ConA)の濃度が20μg/mL以上、且つ、pHが9.0以上となるように用いられることを特徴とする、請求項1に記載のコロナウイルス感染症予防用組成物。
- コンカナバリンA(ConA)の濃度が20~80μg/mLの範囲、且つ、pHが9.0~11.0の範囲となるように用いられることを特徴とする、請求項2に記載のコロナウイルス感染症予防用組成物。
- コロナウイルス感染症が、新型コロナウイルス感染症(COVID-19)であることを特徴とする、請求項1から3の何れかに記載のコロナウイルス感染症予防用組成物。
- コンカナバリンA(ConA)を含有するナタマメ粉末と、アルカリ成分として水酸化カルシウムとを含有することを特徴とする、請求項1から3の何れかに記載のコロナウイルス感染症予防用組成物。
- 飴、ガム又トローチであることを特徴とする、請求項1から3の何れかに記載のコロナウイルス感染症予防用組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022047380 | 2022-03-23 | ||
JP2022047380 | 2022-03-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023143850A true JP2023143850A (ja) | 2023-10-06 |
JP7495762B2 JP7495762B2 (ja) | 2024-06-05 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008523153A (ja) | 疾病の伝染を減少させる組成物及び方法 | |
RU2524304C2 (ru) | Применение соли ацетилсалициловой кислоты для лечения вирусных инфекций | |
EA037085B1 (ru) | Композиция для устранения заложенности носа, обладающая противовирусным действием | |
US20210220378A1 (en) | N-acetylneuraminic acid compositions and methods of use | |
US20230165851A1 (en) | 6'-methoxycinchonan-9-ols for the treatment of coronaviral infections | |
KR20080084992A (ko) | 엘더베리 추출물의 용도 | |
JP2013508309A (ja) | 風邪およびインフルエンザの治療のためのショウガおよびアキノキリンソウを含む草本組成物 | |
EP4137511A1 (en) | New composition for use to treat and prevent infections by covid-19 and other coronaviruses | |
Noureen et al. | Natural Immunity Boosters as Therapeutic Interventions in the Era of the COVID-19 Pandemic | |
EP1437134A1 (en) | Anti-influenza drugs | |
JP7495762B2 (ja) | 新型コロナウイルス感染症(covid-19)予防用組成物 | |
JP2023143850A (ja) | コロナウイルス感染症予防用組成物 | |
JP7084627B2 (ja) | ウイルス感染症予防用組成物 | |
WO2021215938A1 (en) | Anti-viral methods and compositions | |
US7390515B2 (en) | Methods of treating viral infections using berry juice fractions | |
WO2021191904A1 (en) | Methods for preventing and treating viral infection | |
Scherließ et al. | Novel formulation concept for particulate uptake of vaccines via the nasal associated lymphoid tissue | |
US20230226136A1 (en) | A synergistic formulation for management of respiratory pathogens including coronaviruses | |
US20220362190A1 (en) | Viral inactivation spray and gargling formulation | |
Fasogbon et al. | Positive therapeutic role of some selected food and plant on covid-19: a review | |
KR20130030620A (ko) | 택사 추출물을 유효성분으로 함유하는 폐기종 및 폐고혈압 예방 및 치료용 조성물 | |
WO2024096743A1 (en) | Sars-cov-2 binding antibody | |
RU2773149C2 (ru) | Композиции и способы для защиты от присутствующих в воздухе патогенов и раздражителей | |
KR20230014044A (ko) | 코로나 바이러스 증식 억제 조성물 | |
CN116096366A (zh) | 植物化学物质组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231129 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20231129 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240123 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240319 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240514 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240517 |